ENLV
Enlivex Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ENLV
Enlivex Therapeutics Ltd.
A clinical-stage macrophage reprogramming immunotherapy company
14 Einstein Street, Ness-Ziona, Israel 7403618
Focus on identifying, licensing, acquiring, developing and marketing drugs for the treatment of rare and rare genetic diseases.
Enlivex Therapeutics Ltd., an Israeli company headquartered in Tel Aviv, was established on January 22, 2012. The company is a still developing biopharmaceutical company focused on identifying, licensing, acquiring, developing and marketing drugs for the treatment of rare and rare genetic diseases. The company seeks a solution that identifies the pathophysiological mechanisms common to several diseases included. The company focuses on the manifestations of rare diseases, has clear medical needs, and the biological mechanisms of action are well known, and there is no satisfactory treatment for them.
Company Financials
EPS
ENLV has released its 2024 Q3 earnings. EPS was reported at -0.12, versus the expected -0.16, beating expectations. The chart below visualizes how ENLV has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
